A Phase 3 Study of I-Metaiodobenzylguanidine or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)

Go Back to All Clinical Trials

A Phase 3 Study of I-Metaiodobenzylguanidine or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Germ Cell Tumours
Age: Between 11 Year(s) - 45 Year(s)
Gender: Male or Female

Other Inclusion Criteria:

1) Patients who have a diagnosis of neuroblastoma or ganglioneuroblastoma. 2) Patients who are recognized to have high risk disease must have had no prior systematic therapy.

You may not be eligible for this study if the following are true:

1) Patients who have an INRG Stage L2 tumor without amplification of MYCN regardless of tumor histology. 2) Patients with bone marrow failure syndromes.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies